Oulu Center for Cell-Matrix Research, Biocenter and Department of Medical Biochemistry and Molecular Biology, University of Oulu, Oulu, Finland.
BMC Med Genet. 2012 Apr 10;13:26. doi: 10.1186/1471-2350-13-26.
Primary osteoporosis is a rare childhood-onset skeletal condition whose pathogenesis has been largely unknown. We have previously shown that primary osteoporosis can be caused by heterozygous missense mutations in the Low-density lipoprotein receptor-related protein 5 (LRP5) gene, and the role of LRP5 is further investigated here.
LRP5 was analyzed in 18 otherwise healthy children and adolescents who had evidence of osteoporosis (manifested as reduced bone mineral density i.e. BMD, recurrent peripheral fractures and/or vertebral compression fractures) but who lacked the clinical features of osteogenesis imperfecta (OI) or other known syndromes linked to low BMD. Also 51 controls were analyzed. Methods used in the genetic analyses included direct sequencing and multiplex ligation-dependent probe amplification (MLPA). In vitro studies were performed using luciferase assay and quantitative real-time polymerase chain reaction (qPCR) to examine the effect of two novel and three previously identified mutations on the activity of canonical Wnt signaling and on expression of tryptophan hydroxylase 1 (Tph1) and 5-hydroxytryptamine (5-Htr1b).
Two novel LRP5 mutations (c.3446 T > A; p.L1149Q and c.3553 G > A; p.G1185R) were identified in two patients and their affected family members. In vitro analyses showed that one of these novel mutations together with two previously reported mutations (p.C913fs, p.R1036Q) significantly reduced the activity of the canonical Wnt signaling pathway. Such reductions may lead to decreased bone formation, and could explain the bone phenotype. Gut-derived Lrp5 has been shown to regulate serotonin synthesis by controlling the production of serotonin rate-limiting enzyme, Tph1. LRP5 mutations did not affect Tph1 expression, and only one mutant (p.L1149Q) reduced expression of serotonin receptor 5-Htr1b (p < 0.002).
Our results provide additional information on the role of LRP5 mutations and their effects on the development of juvenile-onset primary osteoporosis, and hence the pathogenesis of the disorder. The mutations causing primary osteoporosis reduce the signaling activity of the canonical Wnt signaling pathway and may therefore result in decreased bone formation. The specific mechanism affecting signaling activity remains to be resolved in future studies.
原发性骨质疏松症是一种罕见的儿童期起病的骨骼疾病,其发病机制在很大程度上尚不清楚。我们之前已经表明,原发性骨质疏松症可能是由载脂蛋白受体相关蛋白 5(LRP5)基因的杂合错义突变引起的,在这里进一步研究了 LRP5 的作用。
分析了 18 名无其他健康问题的儿童和青少年的 LRP5 基因,这些患者有骨质疏松的证据(表现为骨矿物质密度降低,即 BMD、复发性外周骨折和/或椎体压缩性骨折),但缺乏成骨不全症(OI)或其他与低 BMD 相关的已知综合征的临床特征。还分析了 51 名对照者。遗传分析中使用的方法包括直接测序和多重连接依赖性探针扩增(MLPA)。进行了体外研究,使用荧光素酶测定和实时定量聚合酶链反应(qPCR)来检查两种新发现的突变和三种先前鉴定的突变对经典 Wnt 信号通路活性以及色氨酸羟化酶 1(Tph1)和 5-羟色胺(5-Htr1b)表达的影响。
在两名患者及其受累家族成员中发现了两种新的 LRP5 突变(c.3446 T > A;p.L1149Q 和 c.3553 G > A;p.G1185R)。体外分析表明,其中一种新突变与两种先前报道的突变(p.C913fs、p.R1036Q)一起,显著降低了经典 Wnt 信号通路的活性。这种减少可能导致骨形成减少,并解释了骨骼表型。肠道衍生的 Lrp5 已被证明通过控制 5-羟色胺限速酶 Tph1 的产生来调节 5-羟色胺的合成。LRP5 突变不影响 Tph1 的表达,只有一种突变(p.L1149Q)降低了 5-羟色胺受体 5-Htr1b 的表达(p < 0.002)。
我们的结果提供了关于 LRP5 突变及其对青少年原发性骨质疏松症发病机制的影响的更多信息。引起原发性骨质疏松症的突变降低了经典 Wnt 信号通路的信号活性,因此可能导致骨形成减少。影响信号活性的具体机制仍需在未来的研究中解决。